# A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

> **NCT03303521** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 196 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sodium Zirconium Cyclosilicate (ZS)

## Key facts

- **NCT ID:** NCT03303521
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2018-11-07
- **Final completion:** 2018-11-07
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303521, "A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03303521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*